New Covid-19 Booster Vaccine Unveiled by Biden Administration
Top health officials in President Biden’s administration announced on Wednesday that a Covid-19 booster shot for those who received the Pfizer or Moderna vaccine is in the works.
Starting September 20, those who are eligible will be offered a chance to receive the additional shot. Eligibility begins eight months after the recipient’s second dose.
As the Delta variant surges throughout the nation, cases in Florida and Texas are unlike anything the states have seen even before vaccines, and health experts are working vigilantly to fight against the variant.
Delta is known to be highly contagious, leading to a weakening defense against infection regardless of vaccination status. But, despite this, unvaccinated individuals still make up 99 percent of coronavirus deaths.
More importantly despite the possibility of breakthrough infection and able to infect others, inevitably vaccinated individuals are still protected against severe infection and fatality plus reduced hospital admission and ICU beds utilisation. Please get vaccinated.
— Noor Hisham Abdullah (@DGHisham) August 21, 2021
This statistic proves the intended effectiveness of the vaccine, which was created to prevent life-threatening hospitalizations. Breakthrough infections were expected, but it was understood they would more commonly result in a mild case.
Experts are still waiting for an advisory on Johnson & Johnson booster shots with data still being collected before devising a proper plan.
The FDA has already approved a third dose for immunocompromised people, described as “solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.”
As of August 20, over half of the United States population is vaccinated, translating to 51.7% of Americans ages 12 and up.
Well cool. Took my kids being back for 3 days to get to quarantine due to a covid exposure. Very cool.
— ennui are the world (@roto_tudor) August 21, 2021
According to NPR, early findings of vaccination trials for children under 12 may be safe for widespread use sometime this Fall. This subset of kids currently represents 14.4 percent of COVID-19 cases in the US.
